| HER2-low breast cancer: molecular characteristics and prognosis E Agostinetto, M Rediti, D Fimereli, V Debien, M Piccart, P Aftimos, ... Cancers 13 (11), 2824, 2021 | 138 | 2021 |
| Immunotherapy in breast cancer: an overview of current strategies and perspectives V Debien, A De Caluwé, X Wang, M Piccart-Gebhart, VK Tuohy, ... NPJ Breast Cancer 9 (1), 7, 2023 | 96 | 2023 |
| Sarcomatoid dedifferentiation in renal cell carcinoma: from novel molecular insights to new clinical opportunities V Debien, J Thouvenin, V Lindner, P Barthélémy, H Lang, R Flippot, ... Cancers 12 (1), 99, 2019 | 29 | 2019 |
| CDK4/6 and PI3K inhibitors: a new promise for patients with HER2‐positive breast cancer E Agostinetto, V Debien, GN Marta, M Lambertini, M Piccart‐Gebhart, ... European journal of clinical investigation 51 (7), e13535, 2021 | 19 | 2021 |
| Predictive biomarkers for response to immunotherapy in triple negative breast cancer: promises and challenges X Wang, L Collet, M Rediti, V Debien, A De Caluwé, D Venet, E Romano, ... Journal of clinical medicine 12 (3), 953, 2023 | 16 | 2023 |
| Avelumab as the basis of neoadjuvant regimen in platinum-eligible and-ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial. N Martinez Chanza, A Carnot, P Barthelemy, V Casert, L Staudacher, ... Journal of Clinical Oncology 40 (16_suppl), 4517-4517, 2022 | 13 | 2022 |
| Involvement of neutrophils in metastatic evolution of pancreatic neuroendocrine tumors V Debien, G Davidson, P Baltzinger, JE Kurtz, F Séverac, A Imperiale, ... Cancers 13 (11), 2771, 2021 | 10 | 2021 |
| DECRESCENDO: De-escalation of adjuvant chemotherapy in patients with HER2+/HR-/node-negative early breast cancer who achieve pCR after neoadjuvant taxane and subcutaneous dual … V Debien, V Adam, R Caparica, D Fumagalli, C Velghe, J Gaye, ... Journal of Clinical Oncology 40 (16_suppl), TPS621-TPS621, 2022 | 8 | 2022 |
| Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis D Martins-Branco, G Nader-Marta, A Tecic Vuger, V Debien, L Ameye, ... Journal of Cancer Research and Clinical Oncology 149 (7), 3075-3080, 2023 | 7 | 2023 |
| Antibody–drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment G Nader-Marta, C Molinelli, V Debien, D Martins-Branco, P Aftimos, ... Therapeutic Advances in Medical Oncology 15, 17588359231183679, 2023 | 6 | 2023 |
| LBA17 Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti … L Buisseret, D Loirat, PG Aftimos, K Punie, C Maurer, V Debien, ... Annals of Oncology 33, S1385, 2022 | 6 | 2022 |
| Optimizing treatment for HER2-positive HR-positive breast cancer V Debien, E de Azambuja, M Piccart-Gebhart Cancer Treatment Reviews 115, 102529, 2023 | 5 | 2023 |
| Molecular analysis for refractory rare cancers: sequencing battle continues–learnings for the MOSCATO-01 study V Debien, S Vignot, C Massard, G Malouf, A Hollebecque, JY Scoazec, ... Critical Reviews in Oncology/Hematology 181, 103888, 2023 | 5 | 2023 |
| Post-neoadjuvant treatment strategies for patients with early breast cancer E Agostinetto, F Jacobs, V Debien, A De Caluwé, CF Pop, X Catteau, ... Cancers 14 (21), 5467, 2022 | 5 | 2022 |
| Le syndrome de lésion réversible du corps calleux (RESLES): une cause rare d’hallucinations d’origine médicamenteuse V Debien, MC Dalmas, MC Taquet, C Maire, S Weibel, JL Dietemann, ... La Revue de Médecine Interne 36, A195-A196, 2015 | 4 | 2015 |
| Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab V Debien, GN Marta, E Agostinetto, M Sirico, F Jacobs, C Molinelli, ... Critical reviews in oncology/hematology, 104089, 2023 | 3 | 2023 |
| DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer V Debien, V Adam, E Coart, E Agostinetto, T Goulioti, C Molinelli, ... Future Oncology 19 (24), 1655-1667, 2023 | 3 | 2023 |
| Abstract OT1-18-02: first-line chemo-immunotherapy with durvalumab, paclitaxel and carboplatin with or without anti-CD73 antibody oleclumab in advanced or metastatic triple … V Debien, C Maurer, P Aftimos, F Clatot, D Loirat, K Punie, F Ghiringhelli, ... Cancer Research 82 (4_Supplement), OT1-18-02-OT1-18-02, 2022 | 3 | 2022 |
| Epigenetic alterations in kidney cancers A Helleux, V Debien, A Fadloun, M Rippinger, S Lebedinsky, I Davidson, ... Bulletin du cancer 106 (10), 839-841, 2019 | 3 | 2019 |
| HER2-low breast cancer: molecular characteristics and prognosis. Cancers (Basel). 2021 E Agostinetto, M Rediti, D Fimereli, V Debien, M Piccart, P Aftimos | 3 | |
